Know Cancer

or
forgot password

Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy in Operable Non Small Cell Lung Cancer


Phase 2
18 Years
65 Years
Not Enrolling
Both
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy in Operable Non Small Cell Lung Cancer


Inclusion Criteria:



- histologic or cytologic diagnosis of operable non-small cell lung cancer (IB-IIIA)

- no prior chemotherapy

- WHO criteria for disease status assessment

Exclusion Criteria:

- Concurrent administration of any other tumor therapy

- pregnant or breast feeding

- serious concomitant disorders

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Antitumor activity

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Investigator Role:

Study Director

Investigator Affiliation:

Eli Lilly and Company

Authority:

Russia: Pharmacological Committee, Ministry of Health

Study ID:

7410

NCT ID:

NCT00191841

Start Date:

December 2002

Completion Date:

February 2006

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung

Name

Location